Amgen (AMGN): Kyprolis Fails to Show PFS Benefit - BMO
- Top 10 News for 10/17 - 10/21: Merger Rumors Abound; CEOs Depart; Tesla Kicks Autopilot Up A Notch
- Wall Street ends little changed; Microsoft hits record
- AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
- Rockwell Automation (ROK) Said to Attract Takeover Interest from Schneider Electric - Source
- British American Tobacco Offers to Acquire Remaining Shares of Reynolds American (RAI) for $56.50/Share
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
BMO Capital analyst, Ian Somaiya, reiterated his Outperform rating on shares of Amgen (NASDAQ: AMGN) after Kyprolis failed to show a PFS benefit versus Velcade in front-line myeloma.
These results do not impact the analyst's estimates but they do eliminate ~ $1.5bn in potential upside.
Kyprolis now faces increased risk from generic Velcade as positive data could reduce pressure from payors to switch to generic. The majority of impact will be in Europe as melphalan/prednisone regimens have limited (<5%) US use.
No change to the price target of $190.
Shares of Amgen closed at $173.53 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amgen (AMGN) Announces XGEVA vs. Zoledronic Acid Study Met Primary Endpoint; Secondary Endpoints Missed
- Jefferies Raises Price Target on ICON plc (ICLR) to $87.50; Reiterates Hold
- PayPal (PYPL) PT Lifted to $48 at Mizuho Following Solid Q3
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesBMO Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!